These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20689436)

  • 21. Mechanisms of chronic cardiac allograft rejection.
    Costello JP; Mohanakumar T; Nath DS
    Tex Heart Inst J; 2013; 40(4):395-9. PubMed ID: 24082367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allograft vasculopathy versus atherosclerosis.
    Rahmani M; Cruz RP; Granville DJ; McManus BM
    Circ Res; 2006 Oct; 99(8):801-15. PubMed ID: 17038650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat.
    Syrjälä SO; Keränen MA; Tuuminen R; Nykänen AI; Tammi M; Krebs R; Lemström KB
    J Heart Lung Transplant; 2010 Sep; 29(9):1047-57. PubMed ID: 20591689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts.
    Libby P; Tanaka H
    Clin Transplant; 1994 Jun; 8(3 Pt 2):313-8. PubMed ID: 7520306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers of heart transplant rejection: the good, the bad, and the ugly!
    Labarrere CA; Jaeger BR
    Transl Res; 2012 Apr; 159(4):238-51. PubMed ID: 22424428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy.
    Yamaura K; Ito K; Tsukioka K; Wada Y; Makiuchi A; Sakaguchi M; Akashima T; Fujimori M; Sawa Y; Morishita R; Matsumoto K; Nakamura T; Suzuki J; Amano J; Isobe M
    Circulation; 2004 Sep; 110(12):1650-7. PubMed ID: 15364799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting the development of cardiac allograft vasculopathy.
    Seki A; Fishbein MC
    Cardiovasc Pathol; 2014; 23(5):253-60. PubMed ID: 24972526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac allograft vasculopathy--a changing perspective.
    Russell ME
    Z Kardiol; 2000; 89 Suppl 9():IX/6-10. PubMed ID: 11151796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments.
    Suzuki J; Isobe M; Morishita R; Nagai R
    Circ J; 2010 Feb; 74(2):233-9. PubMed ID: 20009354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco smoke exposure in either the donor or recipient before transplantation accelerates cardiac allograft rejection, vascular inflammation, and graft loss.
    Khanna AK; Xu J; Uber PA; Burke AP; Baquet C; Mehra MR
    Circulation; 2009 Nov; 120(18):1814-21. PubMed ID: 19841304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis.
    Tuuminen R; Nykänen A; Keränen MA; Krebs R; Alitalo K; Koskinen PK; Lemström KB
    Transplant Proc; 2006 Dec; 38(10):3271-3. PubMed ID: 17175246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cytokines in non-alcoholic steatohepatitis. A review.
    Copaci I; Micu L; Voiculescu M
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):363-73. PubMed ID: 17205149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New evidence for a role of allograft accommodation in long-term tolerance.
    Heslan JM; Renaudin K; Thebault P; Josien R; Cuturi MC; Chiffoleau E
    Transplantation; 2006 Nov; 82(9):1185-93. PubMed ID: 17102770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injury of the coronary endothelium at implantation increases endothelial dysfunction and intimal hyperplasia after heart transplantation.
    El-Hamamsy I; Stevens LM; Vanhoutte PM; Perrault LP
    J Heart Lung Transplant; 2005 Mar; 24(3):251-8. PubMed ID: 15737750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming Chronic Rejection-Can it B?
    Kwun J; Knechtle SJ
    Transplantation; 2009 Oct; 88(8):955-61. PubMed ID: 19855237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac allograft vasculopathy: current concepts.
    Ventura HO; Smart FW; Stapleton DD; Toups T; Price HL
    J La State Med Soc; 1993 May; 145(5):195-8, 200-2. PubMed ID: 8393471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.
    Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD
    J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E; Kushwaha SS
    Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation.
    Iwanaga K; Hasegawa T; Hultquist DE; Harada H; Yoshikawa Y; Yanamadala S; Liao H; Visovatti SH; Pinsky DJ
    Transplantation; 2007 Mar; 83(6):747-53. PubMed ID: 17414708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions.
    Hosenpud JD; Shipley GD; Wagner CR
    J Heart Lung Transplant; 1992; 11(1 Pt 1):9-23. PubMed ID: 1540617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.